Advanced Search
SUN Jianhua, JI Zhonghe, YU Yang, WU Haitao, LI Yan. Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 282-286. DOI: 10.3971/j.issn.1000-8578.2016.04.009
Citation: SUN Jianhua, JI Zhonghe, YU Yang, WU Haitao, LI Yan. Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 282-286. DOI: 10.3971/j.issn.1000-8578.2016.04.009

Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer

More Information
  • Received Date: June 22, 2015
  • Revised Date: November 26, 2015
  • Objective To evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) on patients with peritoneal carcinomatosis (PC) from advanced/ recurrent epithelial ovarian cancer (EOC). Methods We included 46 patients with advanced EOC (FIGO stage Ⅲc/Ⅳ, n=16, Group A) and recurrent EOC with PC (n=30, Group B) treated by CRS+HIPEC procedures. The primary endpoint was overall survival (OS) from the first treatment to disease-related death. The secondary endpoints were safety profiles. Results The median OS was 74.0 months (95%CI: 8.5-139.5) in Group A vs. 57.5 months (95%CI: 29.8-85.2) in Group B (P=0.68). The median OS for patients with PCI≤20 vs. PCI>20 were 76.6 months (95%CI: 56.5-96.7) vs. 38.5 months (95%CI: 24.2-52.8) (P=0.01). The median OS for patients with CC0-1 vs. CC2-3 were 79.5 months (95%CI: 64.8-94.2) vs. 24.3 months (95%CI: 13.9-34.7) (P=0.00). In the recurrent group, the median OS were 65.3 months (95%CI: 42.6-88.9) for platinum-sensitive patients vs. 20.0 months (95%CI: 14.5-23.5) for platinum resistant patients (P=0.05). There was no perioperative death. Postoperative adverse events occurred in five patients. Multivariate analysis revealed that CC0-1 and chemotherapy ≥ six cycles were the independent factors for OS improvement. Conclusion For patients with PC from advanced/recurrent EOC, CRS plus HIPEC could improve the OS with acceptable safety profiles, particularly for advanced EOC PC patients.
  • [1]
    Hennessy BT, Coleman RL, Markman M. Ovarian cancer[J]. Lancet, 2009, 374(9698): 1371-82.
    [2]
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer[J]. N Engl J Med, 1996, 33 4(1): 1-6.
    [3]
    Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21 (17): 3194-200.
    [4]
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20 (5): 1248-59.
    [5]
    van Driel WJ, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer[J]. Curr Treat Options Oncol, 2015, 16(4): 14.
    [6]
    Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment[J]. Expert Opin Pharmacother, 2014, 15(5): 623-36.
    [7]
    Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends[J]. Eur J Surg Oncol, 2010, 36(7): 599-603.
    [8]
    Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia[J]. Ann Surg Oncol, 2010, 17(6): 1710-2.
    [9]
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. J Clin Oncol, 20 12, 30(20): 2449-56.
    [10]
    Huang CQ, Yang XJ, Yu Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase Ⅱ study from a Chinese center[J]. PLoS One, 2014, 9(9): e108509.
    [11]
    Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 20 11, 18(6): 1575-81.
    [12]
    Li Y, Zhou YF, Liang H, et al. Expert consensus on the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis[J]. Zhongguo Zhong Liu Lin Chuang, 2015, 42(4): 198-206. [李雁, 周云峰, 梁 寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专 家共识[J]. 中国肿瘤临床, 2015, 42(4): 198-206.]
    [13]
    Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer[J]. Cancer Chemother Pharmacol, 19 99, 43 Suppl: S15-25.
    [14]
    Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome[J]. Eur J Surg Oncol, 2001, 27 (3): 239-43.
    [15]
    Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer[J]. Semin Oncol, 2007, 34(2 Suppl 2): S1-15.
    [16]
    Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer[J]. J Surg Oncol, 2010, 102(6): 663-70.
    [17]
    Ansaloni L, Agnoletti V, Amadori A, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2012, 22(5): 778-85.
    [18]
    Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer[J]. Ann Surg Oncol, 20 12, 19(7): 2352-9.
    [19]
    Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study[J]. Ann Surg Oncol, 2015, 22(5): 15 70-5.
    [20]
    Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results[J]. J Cancer Res Clin Oncol, 2009, 13 5(12): 1637-45.
    [21]
    Cascales Campos P, Gil J, Parrilla P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer[J]. Eur J Surg Oncol, 2014, 40 (8): 970-5.
    [22]
    Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients[J]. Eur J Surg Oncol, 2013, 39(12): 14 35-43.
    [23]
    Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients[J]. Ann Surg Oncol, 2012, 19 (13): 4052-8.
  • Related Articles

    [1]ZHANG Qinfen, CHANG Jingyao, CAI Yunlang. Meta-analysis of Relationship Between Expression Level of Human Epididymis Protein 4 and Lymph Node Metastasis in Endometrial Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 944-951. DOI: 10.3971/j.issn.1000-8578.2022.21.1513
    [2]TIAN Xin, MO Ligen, LUO Ying. Relative Factors and Surgical Treatment of Neck Lymph Node Metastasis of cN0 Tongue Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 751-755. DOI: 10.3971/j.issn.1000-8578.2014.07.014
    [3]YANG Runxiang, LIU Lin, MA Fei, Qian Haili, YANG Fang. Correlation between Expression of CCR7, D2-40 and Lymphatic Metastases in Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016
    [4]Chen Junying, Yao Desheng, Wu Zhijuan. Diagnostic Value of Serum Squamous Cell Carcinoma Antigen on Lymphatic Metastasis in Cervical Cancer:a Meta analysis[J]. Cancer Research on Prevention and Treatment, 2012, 39(07): 811-817. DOI: 10.3971/j.issn.1000-8578.2012.07.012
    [5]Duan Xiaofeng, Gao Xiaoxu, Gu Xianwen. Surgical Experiences in 76 Cases of Lymphatic Metastasis Recurrence with Postesophagectomy[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 563-566. DOI: 10.3971/j.issn.1000-8578.2012.05.017
    [6]SUN Wei, ZHOU Xiao-jun, MA Heng-hui, ZHANG Ru-song, LU Zhen-feng. Detection of Lymphatic Microvessel Density in Primary Gastric Adenocarcinoma and Its Clinicopathological Significance[J]. Cancer Research on Prevention and Treatment, 2008, 35(07): 512-514. DOI: 10.3971/j.issn.1000-8578.1861
    [7]WANG Rui, CHEN Rui, YANG Wan-hua, MA Xiang-yi, WANG Shi-xuan, LU Yun-ping, MA Ding. Expression of VEGF-C and VEGF-R3 in Breast Cancer and the Relation with Lymphatic Metastasis[J]. Cancer Research on Prevention and Treatment, 2006, 33(06): 385-387,. DOI: 10.3971/j.issn.1000-8578.2883
    [8]HAN Shou-yun, XIA Huo-sheng, LI Ping, et al, . Tracheoesophageal groove huge lymph node metastasis of esophageal carcinoma 15 cases report[J]. Cancer Research on Prevention and Treatment, 2003, 30(06): 509-510. DOI: 10.3971/j.issn.1000-8578.2927
    [9]WANG Jing hua, LI Gui yuan, CHEN Long bang, et al, . Expressions of VEGF,p53 and MMP-2 in human non-small cell lung cancer and the relationship between them and tumor angiogenesis and lymph node metastasis[J]. Cancer Research on Prevention and Treatment, 2003, 30(01): 39-41. DOI: 10.3971/j.issn.1000-8578.88
    [10]Yang Jiesheng, . 12 Ccses of Submucosal Carcinoma of Esophagus with Lymphatic Metastasis[J]. Cancer Research on Prevention and Treatment, 1998, 25(5): 387-388.

Catalog

    Article views (1775) PDF downloads (703) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return